Dr. Siddiqi on CAR T-Cell Therapy in Relapsed/Refractory CLL/SLL

Tanya Siddiqi, MD
Published: Friday, Jun 21, 2019



Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope in Duarte, CA, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Patients who have relapsed/refractory CLL or SLL and fail ibrutinib (Imbruvica) or venetoclax (Venclexta) have an unmet need for appropriate therapy, says Siddiqi.

The TRANSCEND CLL 004 trial, an open-label, multicenter study, enrolled patients who had received ≥2 lines of therapy, including BTK inhibitors, to receive the investigational CAR T-cell product, lisocabtagene maraleucel (JCAR017). The best overall response rate in 15 evaluable patients was 87%, with 7 patients (47%) achieving complete response.

Eradication of minimal residual disease in the blood was also seen in 67% of patients by day 30, making this an excellent option for this patient population, Siddiqi concludes.

<<< 15th International Conference on Malignant Lymphoma


Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope in Duarte, CA, discusses the phase I/II TRANSCEND CLL 004 trial, which evaluated the efficacy of anti-CD19 CAR T cells in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Patients who have relapsed/refractory CLL or SLL and fail ibrutinib (Imbruvica) or venetoclax (Venclexta) have an unmet need for appropriate therapy, says Siddiqi.

The TRANSCEND CLL 004 trial, an open-label, multicenter study, enrolled patients who had received ≥2 lines of therapy, including BTK inhibitors, to receive the investigational CAR T-cell product, lisocabtagene maraleucel (JCAR017). The best overall response rate in 15 evaluable patients was 87%, with 7 patients (47%) achieving complete response.

Eradication of minimal residual disease in the blood was also seen in 67% of patients by day 30, making this an excellent option for this patient population, Siddiqi concludes.

<<< 15th International Conference on Malignant Lymphoma



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x